Skeletal Muscle Mass Loss During Cancer Treatment: Differences by Race and Cancer Site

Abstract

To examine skeletal muscle mass change in a racially diverse sample of patients undergoing cancer treatment, determine significant predictors of muscle mass loss, and explore the interaction of race and cancer site. SAMPLE & SETTING:A retrospective analysis was conducted for 212 patients seeking treatment at a university hospital clinic. METHODS & VARIABLES:Skeletal muscle mass index (SMI) was determined by computed tomography at the time of cancer diagnosis and with cancer treatment.

The Effectiveness of Sarcopenia Interventions for Cancer Patients Receiving Chemotherapy

“…Findings were different in the 2 studies involving people with breast cancer, 29,30 which showed no significant lean body mass loss after the interventions. In a study that compared loss of SMI among patients with different cancer types, breast cancer patients were found to experience lower SMI loss compared with patients with rectal, prostate gland, lung, and colon cancer 42 . Further research is needed to determine differences in SMI change following a given intervention among people with different types of cancer and different cancer treatments.…”

Feasibility of two levels of protein intake in patients with colorectal cancer: findings from the Protein Recommendation to Increase Muscle (PRIMe) randomized controlled pilot trial

“…Cancer and anticancer treatment negatively affect muscle mass (MM), 1 accelerating its loss, 2 yet therapies to combat this prevalent condition remain to be elucidated. 3 Low MM is associated with decreased physical function, reduced health-related quality of life, increased risk for treatment toxicity, delayed treatment, surgical complications, and shorter survival.…”

Hybrid effectiveness-implementation trial of guided relaxation and acupuncture for chronic sickle cell disease pain (GRACE): A protocol

“…Black Americans continue to suffer from higher morbidity and mortality rates at younger ages due to a nexus of structural disparities [ 1 ], which manifest in high incidence rates and poor health outcomes for many common chronic health conditions [ [2] , [3] , [4] , [5] ]. Institutional policies and implicit biases have resulted in neglect at the point of care [ 6 ], lower rates of insurance [ 7 ], and a decreased level of support for diseases primarily impacting Black people [ 8 ].…”